| Medical and Health Sciences | Lifetime | 367 | GB 42 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 347 | GB 38 | 99.93 |
| Clinical Neurology | Lifetime | 16 | GB 4 | 99.94 |
| Psychiatry and Mental health | Lifetime | 64 | GB 11 | 99.82 |
| Medical Physiology | Lifetime | 401 | GB 44 | 99.35 |
| Complementary and Alternative Medicine | Lifetime | 214 | GB 17 | 98.97 |
| Neuroscience of Neurology | Lifetime | 569 | GB 45 | 95.08 |
| Psychiatry and Mental health | 2021-2025 | 27 | GB 5 | 99.72 |
| Medical Physiology | 2021-2025 | 58 | GB 8 | 99.25 |
| Clinical Neurology | 2021-2025 | 55 | GB 11 | 98.83 |
| Cognitive Neuroscience | 2021-2025 | 517 | GB 59 | 90.08 |
| Neuroscience of Neurology | 2021-2025 | 196 | GB 13 | 88.47 |
| Clinical Pharmacology | 2021-2025 | 395 | GB 32 | 81.87 |
| Ginkgo biloba and Cashew Applications | Lifetime | 1 | GB 1 | 99.88 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 12 | GB 2 | 99.93 |
| Dementia and Cognitive Impairment Research | Lifetime | 25 | GB 5 | 99.91 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 25 | GB 8 | 99.84 |
| Alzheimer's disease research and treatments | Lifetime | 62 | GB 6 | 99.81 |
| Restless Legs Syndrome Research | Lifetime | 23 | GB 3 | 98.98 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 150 | GB 15 | 98.66 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 262 | GB 15 | 97.95 |
| Nuclear Receptors and Signaling | Lifetime | 218 | GB 18 | 96.73 |
| Autism Spectrum Disorder Research | Lifetime | 945 | GB 123 | 96.04 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 123 | GB 13 | 94.32 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 924 | GB 65 | 92.50 |
| Pain Management and Opioid Use | Lifetime | 758 | GB 51 | 93.62 |
| Family Caregiving in Mental Illness | Lifetime | 875 | GB 135 | 84.74 |
| Cerebrovascular and genetic disorders | Lifetime | 695 | GB 67 | 79.89 |
| Hallucinations in medical conditions | Lifetime | 137 | GB 33 | 79.73 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 36 | GB 3 | 99.62 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 36 | GB 4 | 99.24 |
| Alzheimer's disease research and treatments | 2021-2025 | 59 | GB 4 | 99.30 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 75 | GB 7 | 94.06 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 248 | GB 19 | 95.58 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 503 | GB 44 | 92.55 |
| Schizophrenia research and treatment | 2021-2025 | 764 | GB 95 | 87.97 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 82 | GB 4 | 81.89 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 847 | GB 14 | 74.06 |
| Restless Legs Syndrome Research | 2021-2025 | 412 | GB 18 | 62.69 |
| Hallucinations in medical conditions | 2021-2025 | 33 | GB 13 | 62.32 |
| Medicinal Plants and Bioactive Compounds | 2021-2025 | 967 | GB 8 | 28.33 |
